Immunomedics (NASDAQ: IMMU) reported Q3 EPS of ($0.21), $0.06 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $500 million, versus $1.3 million reported last year.

For earnings history and earnings-related data on Immunomedics (IMMU) click here.